Serial evaluation of Protein C and antithrombin in dogs with sepsis

Journal of Veterinary Internal Medicine

Volumn 22, Issue 1, 2008, Pages 26-30

  De Laforcade, A M ^a   Rozanski, E A ^a   Freeman, L M ^a   Li, W ^b  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Anticoagulant; Hemostasis; Infection.

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

EID: 40549137796     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2007.0021.x     Document Type: Article

References (33)

1. 1 Levi M, Ten Cate H, Van der Poll T, et al. Pathogenesis of disseminated intravascular coagulation in sepsis. J Am Med Assoc 1993 ; 270: 975–979.
2. 2 Mavrommatis AC, Theodoridism T, Orfanidou A, et al. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000 ; 28: 451–457.
3. 3 Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. Heamatol 1999 ; 84: 254–259.
4. 4 Gando S, Nanzaki S, Sasaki S, et al. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 1998 ; 26: 2005–2009.
5. 5 Esmon CT, Taylor FB, Snow TR. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991 ; 66: 160–165.
6. 6 Thijs LG, De Boer JP, De Groot M, et al. Coagulation disorders in septic shock. Intens Care Med 1993 ; 19 (Suppl 1): S1–S15.
7. 7 Hesselvik JF, Malm J, Dahlback B. Protein C, protein S and C4b‐binding protein in severe infection and septic shock. Thromb Haemost 1991 ; 65: 126–129.
8. 8 Yan SB, Helterbrand JD, Hartman DL, et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001 ; 120: 915–922.
9. 9 Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992 ; 101: 816–823.
10. 10 Philippe J, Offner F, Declerck PJ, et al. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991 ; 65: 291–295.
11. 11 Lorente JA, Gardia‐Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993 ; 103: 1536–1542.
12. 12 Otto CM, Rieser TM, Brooks MB, et al. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000 ; 217: 1500–1504.
13. 13 De Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 2003 ; 17: 674–679.
14. 14 LaRue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 cases (1986–1987). J Am Vet Med Assoc 1990 ; 197: 1368–1372.
15. 15 Hauptman JG, Walshaw R, Olivier NB. Evaluation of the sensitivity and specificity of diagnostic criteria for sepsis in dogs. Vet Surg 1997 ; 26: 393–397.
16. 16 Maddala GS. Limited‐Dependent and Qualititative Variables in Econometrics. Cambridge, UK: Cambridge University Press ; 1983: 221–256.
17. 17 Greene W. Econometric Analysis, 4th ed. Upper Saddle River, NJ: Prentice Hall ; 2000: 896–938.
18. 18 Leigh JP, Ward MM, Fries JF. Reducing attrition bias with an instrumental variable in a regression model: Results from a panel of rheumatoid arthritis patients. Stat Med 1993 ; 12: 1005–1018.
19. 19 Palmer KG, King LG, Van Winkle TJ. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis. J Am Vet Med Assoc 1998 ; 213: 220–224.
20. 20 Johnson LR, Lappin Mr, Baker DC. Pulmonary thromboembolism in 29 dogs (1985–1995). J Vet Intern Med 1999 ; 13: 338–345.
21. 21 Norris CR, Griffey SM, Samii VF. Pulmonary thromboembolism in cats: 29 cases (1987–1997). J Am Vet Med Assoc 1999 ; 215: 1650–1654.
22. 22 Tanaka T, Tsujinaka T, Kambayashi J, et al. The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model. Thromb Res 1990 ; 60: 321–330.
23. 23 Jaimes F, De La Rosa G, Arango C. A randomized clinical trial of unfractionated heparin for treatment of sepsis (the HETRASE study): Design and rationale. Trials 2006 ; 7: 19.
24. 24 Marlar RA, Endres‐Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985 ; 66: 59–63.
25. 25 Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. 1999 ; 19: 1566–1572.
26. 26 Yamauchi T, Umeda F, Inoguchi T, et al. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989 ; 163: 1404–1411.
27. 27 Uchiba M, Okajima K. Antithrombin III (ATIII) prevents LPS‐induced vascular injury: Novel biological activity of AT III. Semin Thromb Hemost 1997 ; 23: 583–590.
28. 28 Ostrovsky L, Woodman R, Payne D, et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997 ; 96: 2302–2310.
29. 29 Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Sem Thromb Hemost 2006 ; 32 (Suppl 1): 49–60.
30. 30 Van de Wouwer M, Collen D, Conway EM. Thrombomodulin‐protein C‐EPCR system: Integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004 ; 24: 1374–1383.
31. 31 Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin mediated cell adhesion: Role of unique fucosylated oligosaccharide. Glycobiology 1994 ; 4: 221–225.
32. 32 Grey ST, Tsuchida A, Hau H, et al. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN‐gamma, or phorbol ester. J Immunol 1994 ; 153: 3664–3672.
33. 33 Bernard GR, Vincent JL, Laterre PF. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 ; 344: 699–709.